2011
Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Arun B, Bayraktar S, Liu DD, Barrera A, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. Journal Of Clinical Oncology 2011, 29: 3739-3746. PMID: 21900106, PMCID: PMC4874218, DOI: 10.1200/jco.2011.35.2682.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic chemotherapyRelapse-free survivalBreast cancerOS ratesOverall survivalBRCA1 carriersBRCA statusBRCA2 mutationsKaplan-Meier product-limit methodPathologic complete response rateComplete response rateNeoadjuvant systemic therapySingle institution experienceEstrogen receptor negativityBRCA mutation carriersBRCA1 statusIndependent significant predictorsProduct-limit methodMultivariate logistic modelBRCA genetic testingSporadic breast cancerLogistic regression modelsBRCA noncarriersTrastuzumab useSystemic chemotherapy
2009
Triple-negative breast cancer—current status and future directions
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Annals Of Oncology 2009, 20: 1913-1927. PMID: 19901010, DOI: 10.1093/annonc/mdp492.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBasal-like breast cancerBreast cancerBreast cancer—current statusStandard cytotoxic chemotherapy regimensHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Common cytotoxic agentsCytotoxic chemotherapy regimensGrowth factor receptor 2Factor receptor 2Chemotherapy regimensClinical featuresUnfavorable prognosisProgesterone receptorLack of expressionNovel agentsReceptor 2Cytotoxic agentsPrognosisComplete concordanceCancerGene expression analysisHigh-throughput gene expression analysisRegimens